Ultragenyx proposes $138 million Dimension takeover

USA-based rare diseases specialist Ultragenyx Pharmaceutical has made a proposal to acquire all of the outstanding shares of common stock of Dimension Therapeutics for $5.50 per share, or approximately $138 million, in cash.

Dimension Therapeutics is a US gene therapy company focused on rare diseases.